Fig. 4: IDO1 is a predictive biomarker of BCG treatment response. | Cell Death Discovery

Fig. 4: IDO1 is a predictive biomarker of BCG treatment response.

From: Heightened IDO1 levels predict Bacillus Calmette-Guèrin failure in high-risk non-muscle-invasive bladder cancer patients

Fig. 4

A Workflow chart indicating the validation of IDO1 in our cohort of FFPE BC samples. B Representative droplet digital PCR (ddPCR) scatter plots showing positive droplets for IDO1 (blue) and GAPDH (green) used as housekeeping gene of FFPE samples of responder and non-responder BC patient. C Absolute mRNA levels (copies/µl) of IDO1 in responder and non-responder BC patients (n = 23). Data are represented as mean ± SD of three independent experiments. D Representative IHC analysis for IDO1 of patients as in (C). Scale bar is 100 µm. E Representative immunohistochemical analysis for CD8 and granzyme B in BC responder and non-responder BC patients. F Percentage of T cells positive for granzyme B and CD8 in responder and non-responder BC patients, as in (E), normalized to the tumor area analyzed.

Back to article page